The ADAS-cog in Alzheimer's disease clinical trials: Psychometric evaluation of the sum and its parts

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 12, 2010, Pages 1363-1368

  Cano, Stefan J ^a   Posner, Holly B ^b   Moline, Margaret L ^c   Hurt, Stephen W ^c,d   Swartz, Jina ^e   Hsu, Tim ^c   Hobart, Jeremy C ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b PFIZER INC   (United States)

^c EISAI INC   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL;

ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMERS DISEASE ASSESSMENT SCALE COGNITIVE BEHAVIOR SECTION; ARTICLE; COGNITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; RELIABILITY; VALIDITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MASS SCREENING; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMETRICS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 78649633880     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2009.204008     Document Type: Article

References (26)

1. Blennow K, de Leon M, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403.
2. Alzheimer's Association. Alzheimer's disease facts and figures. Chicago: Alzheimers Association, 2008.
3. Brookmeyer R, Johnson E. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007;3:186-91.
4. Aisen P, Schafer K, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819-26.
5. Mohs K, Rosen W, Davis K. The Alzheimer's Disease Assessment Scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983;19:448-50.
6. Rosen W, Mohs R, Davis K. A new rating scale for Alzheimer'sdisease. Am J Psychiatry 1984;141:1356-64.
7. Farlow M, He Y, Tekin S, et al. Impact of APOE in mild cognitive impairment. Neurology 2004;63:1898-901.
8. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane database of systematic reviews. London: St George's Hospital Medical School, 2004.
9. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18.
10. Food and Drug Administration. Patient reported outcome measures: use in medical product development to support labelling claims, 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM193282.pdf (accessed 20 Dec 2009).
11. Hobart J, Cano S, Zajicek J, et al. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 2007;6:1094-105.
12. Kim Y, Nibbelink D, Overall J. Factor structure and reliability of the Alzheimer's Disease Assessment Scale in a multicenter trial with linopirdine. J Geriatr Psychiatry Neurol 1994;7:74-83.
13. Weyer G, Erzigkeit H, Kanowski S, et al. Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial. Int Psychogeriatr 1997;9:123-38. (Pubitemid 27455497)
14. Doraiswamy P, Kaiser L, Bieber F, et al. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate alzheimer's disease. Alzheimer Dis Assoc Disord 2001;15:174-83.
15. Wesnes K, Satek S, Ferguson J, et al. P4-401: identifying cognitive enhancement in man: identifying efficacy in the dementias [abstract]. Alzheimers Dement 2008;4:T792.
16. Dichgans M, Markus H, Salloway S, et al. Donepezil in patients with subcortical vascular cognitive smpairment: a randomised double-blind trial in CADASIL. Lancet Neurol 2008;7:310-18.
17. Novick MR. The axioms and principal results of classical test theory. J Math Psychol 1966;3:1-18.
18. Rogers S, Farlow M, Doody R, et al. A 24-week, double-blind, placebo-controlled trial of donepezil inpatients with Alzheimer's disease. Neurology 1998;50:136-45.
19. Burns A, Rossor M, Gauthier S, et al. The effects of Donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-44.
20. Seltzer B, Zolnouni P, Nunez M, et al. Efficacy of Dopenzil in early-stage Alzheimer disease: a randmoized-controlled trial. Arch Neurol 2004;61:1852-6. (Pubitemid 39612945)
21. Hobart JC, Freeman JA, Lamping DL, et al. The SF-36 in multiple sclerosis (MS): why basic assumptions must be tested. J Neurol Neurosurg Psychiatr 2001;71:363-70.
22. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality of life instruments: attributes and review criteria. Qual life Res 2002;11:193-205.
23. Cano SJ, Hobart JC, Hart P, et al. The International Co-operative Ataxia Rating Scale (ICARS): an appropriate rating scale for Friedreich's Ataxia? Mov Disord 2005;20:1585-91.
24. Hobart J, Cano S. Improving the evaluation of therapeutic intervention in MS: the role of new psychometric methods. Health Technol Assess 2009;13:1-200.
25. Andrich D. Rasch models for measurement. Beverley Hills, CA: Sage Publications, 1988.
26. Rasch G. Probabilistic models for some intelligence and attainment tests. Copenhagen, Denmark: Danish Institute for Education Research, 1960. (Reprinted Chicago, MESA Press University of Chicago, 1980).